Abstract
Historically, HER2-positive breast cancer had a poor prognosis. The development of molecul ar ther apies that target the HER2 receptor has TR ansformed outcomes. Here, the evidence on Anti-HER2 therapies is summarised.
MeSH terms
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / nursing
-
Breast Neoplasms / pathology
-
Female
-
Humans
-
Neoplasm Metastasis*
-
Receptor, ErbB-2 / antagonists & inhibitors*
Substances
-
Antineoplastic Agents, Hormonal
-
ERBB2 protein, human
-
Receptor, ErbB-2